Lyme Disease Vaccine Developed by Stony Brook and Brookhaven Researchers Shows Promise in Clinical Trial
Friday, May 10, 2013
The results of a clinical trial in Europe of an investigational Lyme disease vaccine co-developed by researchers at Stony Brook University, Brookhaven National Laboratory, and at Baxter International Inc. revealed promising results. The vaccine produced substantial antibodies against all targeted species of Borrelia, the causative agent of Lyme disease in Europe and the United States.